Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Seqirus, a global leader in influenza prevention, today presented new real-world evidence (RWE) at the European Scientific Working Group on Influenza ...
Seqirus, a global leader in influenza prevention and influenza pandemic response, today announced the presentation of new data at the European...
Seqirus, a global leader in influenza prevention and influenza pandemic response, today announced new late-breaking data from a systematic review and ...
Seqirus, a global leader in influenza prevention, today presented absolute efficacy data on the company's cell-based quadrivalent influenza vaccine...
Seqirus, a global leader in influenza prevention, today presented new real-world evidence (RWE) on the effectiveness of an MF59®-adjuvanted,...
Seqirus, a global leader in influenza prevention, today announced new, late-breaking real-world evidence (RWE) to be presented at IDWeek 2020...
Seqirus, a global leader in influenza prevention, today announced the publication of new real-world evidence (RWE) that demonstrated an MF59®...
Seqirus, a global leader in influenza prevention, today announced the publication of real-world evidence (RWE) on the company's cell-based...
Seqirus has started shipping its portfolio of seasonal influenza vaccines to United States (U.S.) customers for the upcoming 2020/21 U.S. influenza...
Quadrivalent formulation of the first-and-only adjuvanted seasonal influenza vaccine for older adults (65+ years) receives FDA approval1 Designed...
Seqirus, a global leader in influenza prevention and pandemic response, today announced that the U.S. Food and Drug Administration (FDA) has approved ...
Seqirus announced today results from a prospective, cluster-randomized trial led by a team of researchers from Brown University that showed FLUAD®,...
Seqirus, a leading innovator in influenza vaccines and pandemic preparedness, applauds the Administration for recognizing the urgency of ensuring...
Seqirus, a global leader in influenza prevention, today presented new scientific data at the Options for the Control of Influenza (OPTIONS X)...
Seqirus, a global leader in influenza prevention, today presented data at the Options for the Control of Influenza (OPTIONS X) Conference in...
Seqirus, a global leader in influenza prevention, today announced it will feature data in 3 presentations and 24 posters on the company's adjuvant...
CSL Limited today named Anjana Narain, a seasoned leader in vaccines and biopharmaceuticals, as Executive Vice President and General Manager of its...
Seqirus is first to begin shipping its portfolio of seasonal influenza vaccines for the upcoming 2019/20 U.S. influenza season Seqirus plans to...
Seqirus, a leading innovator in influenza protection, today announced it will file an Annual Strain Update with the U.S. Food and Drug Administration ...
Seqirus, a wholly owned subsidiary of CSL Limited and a global leader in influenza prevention, today announced a $140M expansion of its Holly Springs ...
Seqirus, a global leader in influenza prevention, today released a new real-world evidence analysis indicating that its cell-based quadrivalent...
Seqirus, a global leader in influenza prevention, today announced the U.S. Food and Drug Administration (FDA) has approved AFLURIA® QUADRIVALENT...
Seqirus, a global leader in influenza prevention, today announced data, to be presented at IDWeek 2018 on Saturday, October 6, showing that higher...
Seqirus, a global leader in influenza prevention, will present new healthcare and cost outcomes data for its MF59®-adjuvanted trivalent influenza...
Seqirus, a global leader in influenza vaccine innovation, today announced FDA approval of its next generation cell-based manufacturing process at...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.